mTOR (mTORC1) (inhibitor)

Class

rapamycin analog (rapalog); kinase inhibitor. Binds intracellular FKBP-12 to form a complex that inhibits mTOR complex 1 (mTORC1)

Pathway

inhibition of mTORC1 kinase activity reduces downstream S6 ribosomal protein kinase (S6K1) and 4E-BP1 signaling, both involved in protein synthesis and cell growth; in TSC this reduces the aberrant mTOR pathway activation that drives seizures and tumor growth

Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that functions as the catalytic core of two distinct protein complexes, mTORC1 and mTORC2. mTORC1 acts as a central integrator of nutrient, energy, and growth-factor signals, and when active it promotes protein synthesis, cell growth, and proliferation. In many tumors and in genetic disorders such as tuberous sclerosis complex, upstream regulatory proteins that normally restrain mTORC1 are lost or mutated, leading to persistent, unregulated activation of this pathway and driving abnormal cell and tissue growth, including tumor formation and, in tuberous sclerosis, seizure activity. Rapalogs are a class of small molecules that do not block mTOR directly at its active site; instead, they first bind an intracellular protein called FKBP-12, and this complex then associates with and selectively inhibits mTORC1. By damping mTORC1 output, downstream growth and proliferative signaling is reduced. This mechanism is relevant across oncology, where mTORC1 hyperactivation supports tumor growth, in tuberous sclerosis complex, where it addresses both tumor and seizure manifestations, and in transplantation medicine, where mTORC1 inhibition also suppresses immune cell proliferation.